2021 Fiscal Year Final Research Report
Examination of REV7 expression in mesopharyngeal cancer
| Project/Area Number |
19K18743
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 56050:Otorhinolaryngology-related
|
|---|
| Research Institution | Kitasato University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2019-04-01 – 2022-03-31
|
| Keywords | REV7 / mesopharyngeal cancer |
|---|
| Outline of Final Research Achievements |
We investigated the relationship between REV7 expression and prognosis using cases of mesopharyngeal carcinoma treated in our department.
First, p16 positive and p16 negative cancers were 45% and 55%, respectively, similar to previous reports. Second, there was no relationship between REV7 expression and patient background factors. There was also no relationship between REV7 expression and p16 expression.
Finally, with regard to REV7 expression and prognosis, there was no between REV7 expression and prognosis in all patients; when prognosis was examined by p16 status, the REV7 high expression group had a worse prognosis in p16 negative cancers and the REV7 low expression group in p16 positive cancers.
|
| Free Research Field |
Head and Neck Surgery
|
| Academic Significance and Societal Importance of the Research Achievements |
これまで、遺伝子修復に関わる多機能タンパクであるREV7は、様々な癌腫において高発現であると予後が悪い、また治療抵抗性が高いということが報告されてきた。頭頸部癌領域でのREV7に関わる研究は乏しく、今回我々は中咽頭癌における検討を開始した。中咽頭癌の治療感受性に関して大きな因子はp16発現の有無である。中咽頭癌全体ではREV7発現と予後に関連はなかったが、p16発現の有無で分類するとp16非関連癌ではREV7高発現群の、p16関連癌ではREV7低発現群の予後が悪いことが分かった。これは新しい発見であり、今後REV7発現の抑制で治療抵抗性を変えられる可能性が示唆される有意義な結果と言える。
|
